CCR6 and graft versus host disease: (146) also demonstrated a correlation between CCR6 expression in MHC class II–mismatched T-cells and the associated risk of GVHD in both the skin and GI tract with a significant reduction in the incidence and severity of GVHD in allogenic recipients of CCR6-deficient T-cells.